<DOC>
	<DOCNO>NCT00517985</DOCNO>
	<brief_summary>Recently , antidepressant explore class medication treat major depression context perimenopause , well somatic symptom perimenopause ( hot flash ) . Duloxetine ( Cymbalta ) one new antidepressant approve treatment Major Depressive Disorder ( MDD ) . Therefore , current study design assess efficacy duloxetine sample woman perimenopausal meet criterion MDD . We assess impact MDD perimenopausal symptom .</brief_summary>
	<brief_title>Duloxetine Perimenopausal Depression</brief_title>
	<detailed_description>Over twenty percent woman experience major depressive episode lifetime , prevalence reflect great risk find among men . Perimenopausal depression , postpartum depression , unpleasant , disturb emotional physical symptom occur monthly menstrual period show occur time fluctuate level estrogen gonadal hormone . Perimenopause commonly define time hormonal fluctuation typically occur woman 40-55 year age change menstrual pattern . It demonstrate woman may particularly high risk depressive symptom perimenopause due decline level estrogen . In previous study , woman risk postpartum depression find benefit estrogen replacement therapy . However , hormone replacement therapy ( HRT ) become increasingly controversial light finding Women 's Health Initiative study determine woman receive estrogen plus progestin slightly likely suffer coronary heart disease , stroke , blood clot lung , invasive breast cancer . Since report result , HRT use decline alternative treatment depression , antidepressant increasingly utilized perimenopausal woman . Fluoxetine , paroxetine , venlafaxine member new class drug call selective serotonin reuptake inhibitor ( SSRIs ) demonstrate beneficial treatment hot flash . Recently , new second-generation drug , Duloxetine ( Cymbalta ) , also approve treatment major depression . This drug member class compound refer serotonin-norepinephrine reuptake inhibitor ( SNRIs ) . The method Duloxetine member group achieve effect similar antidepressant agent use . Recent study indicate Duloxetine appear provide relief mood physical component perimenopause . In order continue study benefit Duloxetine subject perimenopause , study design enroll 20 perimenopausal woman depression 9-week trial . Subjects enrol study currently use hormone replacement therapy patient must meet criterion major depressive episode , verify standardize protocol establish depression , Structured Clinical Interview DSM-IV ( SCID ) . Subjects enrol study , undergo 7 total clinic visit 9-week study period . The first visit last approximately 3 hour visit take approximately 45 minute . During 1st visit , medical psychiatric history review blood drawn ( approximately 3 teaspoon ) . Blood use routine laboratory test . Urine also collect pregnancy test . For Major Depressive Disorder , FDA recommend total dose 40 mg/day ( 20 mg take twice day ) 60 mg/day ( give either day 30 mg twice day ) administer without regard meal . While 120 mg/day dose show safe effective , evidence dos higher 60 mg confer additional significant benefit , high dose clearly less well tolerate . During current study , short period time participant receive placebo ( pill look like study drug contain medication ) , although majority study , participant receive actual study medication ( Duloxetine ) . The initial dose Duloxetine give 30 mg dose dosage increase time 60 mg per day . This study blind , mean participant know whether take placebo study drug . However , subject receive duloxetine majority time enrol trial . Investigators know subject receive placebo order maintain blinding study , study staff able tell participant take placebo take Duloxetine . After consent form read sign , participant undergo Structured Clinical Interview DSM-IV ( SCID ) interview . In addition , symptom also rat rating scale include Clinical Global Impression ( CGI ) , Greene Climacteric Scale ( GCS ) Hamilton Depression Rating Scale ( HAM-D ( 17-item ) ) . To determine functional assessment participant , Global Assessment Scale ( GAF ) use . All participant also undergo interview include psychiatric substance use history ( include collection data regard use alcohol , tobacco , illicit substance ) . Medical screen occur conjunction initial entry interview . All patient must gynecologic exam within past year , study personnel provide referral exam . The investigator review patient 's medical history . Laboratory test include thyroid function test ( TFTs ) , liver function test ( LFTs ) , renal panel , pregnancy test , complete blood count ( CBC ) . Subjects also complete Greene Climacteric Scale , use quantify severity perimenopausal symptom . At visit , participant administer CGI , HAM-D , GCS questionnaires/surveys addition The Greene Climacteric Scale , use quantify symptom perimenopause . Also , participant ask visit miss dos particular week . Each office visit last approximately 45 minute . If necessary , telephone contact investigator permissible available 24 hours/day emergency . Safety tolerability assess throughout study . At study visit , information side effect may occur collect . In rare event side effect adverse event occurs , participant able contact study 's research clinician . Emergency contact personnel on-call 24 hour per day , seven day per week .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Women age 40 year old old . Perimenopausal symptoms least 3 month duration , include irregular period and/or hot flash . Minimum score 15 Hamilton Rating Scale Depression ( 17item ) . Subjects must able treated outpatient basis . Subjects must able provide write informed consent . Subjects presently take antidepressant medication . Subjects currently use hormone replacement therapy . Subjects pregnant . Subjects hepatic disease . Other Axis I disorder , except Generalized Anxiety Disorder Panic Disorder . `` Uncontrolled '' narrow angle glaucoma . Known hypersensitivity duloxetine inactive ingredient . Treatment monoamine oxidase inhibitor ( MAOI ) within 14 day study drug administration potential need use MAOI study within 5 day discontinuation study drug . Presence psychotic symptom . History mania hypomania . Hamilton Rating Scale Depression ( HAMD ) suicide item score &gt; 2 . End stage renal disease severe renal impairment . Abnormal uterine bleeding evaluate gynecologist ( heavy prolong uterine bleeding , menstrual period occur frequently every 3 week , bleed sexual intercourse , spot period ) .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>perimenopausal depression</keyword>
	<keyword>duloxetine</keyword>
	<keyword>cymbalta</keyword>
	<keyword>major depressive disorder</keyword>
	<keyword>woman</keyword>
</DOC>